Abio whilst currently tumbling down pyramid slope has no dilution risk with sufficient cash on hand to last a while based on current cash burn and has plenty catalysts. Geometric structure is very supportive of a move to $12 at minimum and more likely $24
I'm really into crypto and I've seen so many things not only from a trading perspective but also mining individual Scrypt + SHA-256 coins...Fidelity is just an island or oasis with the peace of mind when I execute a trade it goes through. I don't have lag, loss of connection, obfuscation or loss of funds from theft on exchanges part. I can put $500 or 2 million...
The company is a very small market cap so it's considerably higher risk than most stocks. Stocks like these require very small positions.
First off, please don't take anything I say as financial advice and as always everything is on an opinion based basis. Pursue your own due diligence. That being said, ABIO seems to have a decent setup for potentially another bull run quite soon. The resistance curve is about to pop and it looks like this is a close watch as with other stocks I been watching. In my...
NASDAQ:ABIO Another possible short for today. After a sharp rise on May 28, the paper could not grow any further. All the growth has already been sold. At 6.81 instrument faced a strong support level. Within 3 days there were a level tests. On June 22, the big long player managed to raise the price slightly from 6.89 to 7.52. However, in the last trading...
Hello, What is ABIO? ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the...
ARCA BIOPHARMA ANNOUNCES AB201 DEVELOPMENT PROGRAM FOR TREATMENT OF COVID-19 ASSOCIATED COAGULOPATHY arcabio.com The Westminster, Colorado-based company said it plans to evaluate AB201, a selective inhibitor of tissue factor, as a potential treatment for COVID-19-associated coagulopathy and the related inflammatory response. Coagulopathy is among the most...
Maybe it's too early to tell but I like it
Upon Request backtest only. I don't trade usually trade penny craps because most of them are a pump and dump scheme. Might take down this "unethical investment" sooner or later.
Be on the watch-out for massive continuation today after great results yesterday. Already up 19% premarket. RESULTS TRANSCRIPT “In the first part of this year, we continued to make progress on our lead development program Gencaro, achieving an agreement with the FDA on our Special Protocol Assessment for the PRECISION-AF Phase 3 clinical trial evaluating Gencaro...
today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 clinical trial, PRECISION-AF, to assess the safety and efficacy of GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with a...
Biggest gapper today #ABIO $ABIO, fell right away at market open. Looks to be setting up some possible support, ill watch it tomorrow and the next few days to see if we can break back above the median. You can visit my youtube and watch my full video recap, link in the description!